



South & Southeast Asia

# Pathogen Genomics Prioritization & Implementation Workshop

September 9-13, 2024  
Bangkok, Thailand

## WORKSHOP PARTNERS





# Arbovirus case study

Pathogen Prioritization Workshop Bangkok  
9<sup>th</sup>- 13<sup>th</sup> September 2024

**Rebecca Rockett**

SydneyID, School of Medical Sciences, USyd

**Ruklanthi (Rukie) de Alwis**

Duke-NUS Medical School Singapore, Asia PGI

## WORKSHOP PARTNERS



## Stillbirths linked to rare disease in Brazil raises fear of Zika re-run

Health ministry sounds alarm over spread of Oropouche after four cases of microcephaly found in newborns of mothers infected with virus

Verity Bowman and Maeve Cullinan, GLOBAL HEALTH SECURITY REPORTER  
25 July 2024 • 12:37pm

## France, rest of Europe could see more local dengue outbreaks as world warms


## The Rising Concern of Malaria and Mosquito-Borne Diseases in the US

Jul 18, 2023  
Benjamin Hottel, PhD, BCE

## 2 cases of rare mosquito-borne disease EEE detected in Alabama, including 1 death

Only one other U.S. case has been reported this year, according to the CDC.

By Mary Kekatos  
August 23, 2023, 7:23 AM



## 2024 Chandipura virus outbreak is the largest in 20 years: WHO

This year's Chandipura virus outbreak is the largest in the past twenty years, with a 33% case fatality rate.

## Warmer rainy season triggers dengue spike across Indonesia

The Health Ministry recorded some 35,500 dengue cases nationwide from the beginning of January to March 18, with 290 deaths.



Nina A. Loasana  
The Jakarta Post


## Rare cases of mosquito- and tick-borne diseases, including Powassan and dengue, crop up across the U.S.

High temperatures may extend the tick and mosquito season into the fall, experts say.



# Increasing threat of arboviruses to human health

- The pandemic potential of arboviruses, particularly in our region is increasing



*Rose-Nunes D et al 2023 Frontiers in Drug Discovery*



# Increasing threat of arboviruses to human health

- The pandemic potential of arboviruses, particularly in our region is increasing
- Driven by urbanization, climate change, human movement and adaptation of mosquitos are increasing the.
- Genomics can have a critical role in arbovirus surveillance

Table 2   Non-climate drivers of the transmission and spread of vector-borne diseases	
<b>Globalization and environment</b>	
Driver	Effect
Deforestation, mining and dams	Change vector and non-human host habitats
Ecosystem degradation/change	Changes vector and non-human host habitats
International travel and trade	Spreads pathogen and vector
Urbanization	Provides an ideal habitat for <i>A. aegypti</i>
Population displacement	Spreads pathogen to new locations or puts immunologically susceptible populations in contact with the vector and pathogen
<b>Sociodemographic factors</b>	
Driver	Effect
Population demographic composition	Children, the elderly and pregnant women may have elevated vulnerability
Level of economic development	Quality of housing (including presence of air conditioning) affects exposure to vectors
Baseline incidence of disease	Vulnerability to climate change may be highest at the margins of current endemic areas
Population health status	Low level of population health increases vulnerability
Humanitarian crises	Rose-Nunes D et al 2023 Frontiers in Drug Discovery

Rocklov J et al, Nature Immunology, 2020






# Arboviruses of public health significance

- Belong to three main viral families,
  - Flaviviruses
  - Alphaviruses
  - Bunyaviruses
- These viruses have different geographical distributions.

Global Spread of Flaviviruses




*Charlier, C et al 2017, Lancet Child & Adol*



# Arboviruses of public health significance

- Belong to three main viral families,
  - Flaviviruses
  - Alphaviruses
  - Bunyaviruses
- These viruses have different geographical distributions.

Global Spread of Alphaviruses




*Charlier, C et al 2017, Lancet Child & Adol*



# Arboviruses of public health significance

- Belong to three main viral families,
  - Flaviviruses
  - Alphaviruses
  - Bunyaviruses
- These viruses have different geographical distributions.

Global Spread of Bunyaviruses




*Charlier, C et al 2017, Lancet Child & Adol*





# Arboviruses of public health significance

- Belong to three main viral families,
  - Flaviviruses
  - Alphaviruses
  - Bunyaviruses
- These viruses have different geographical distributions.
- These viruses are spread by mosquito species.



# Arboviruses of public health significance

- Belong to three main viral families,
  - Flaviviruses
  - Alphaviruses
  - Bunyaviruses
- These viruses have different geographical distributions.
- These viruses are spread by mosquito species.
- Arboviruses of importance to Asia

Dengue  
virus

Zika virus

Chikungunya  
virus

Japanese  
encephalitis

West Nile  
virus

Arbovirus X



# Many more important arboviruses


- Over 500 arboviruses have been described
- WHO has initially focused transmission via *Aedes spp.* vectors
- Dengue, Zika, Yellow fever, Chikungunya*

Virus Family	Viral Genus	Virus	Vector Species
Bunyaviridae	Orthobunyavirus	California serogroup viruses	Mosquito (Aedes sp.)
	Phlebovirus	Rift Valley Fever virus	Mosquito (various)
	Phlebovirus	Toscana virus	Sandfly (Phlebotomus sp.)
	Phlebovirus	Phlebotomus fever virus	Sandfly (phlebotomus)
	Phlebovirus	Sandfly Fever Naples virus	Sandfly (phlebotomus)
	Phlebovirus	Sandfly Fever Sicilian virus	Sandfly (phlebotomus)
	Phlebovirus	Heartland virus	Tick (A. americanum)
Flaviviridae	Phlebovirus	Severe fever with thrombocytopenia syndrome virus	Tick (H. longicornis)
	Nairovirus	Crimean Hemorrhagic Fever virus	Tick (Hyalomma sp.)
	Flavivirus	Dengue Virus	Mosquito (Aedes sp.)
	Flavivirus	Zika virus	Mosquito (Aedes sp.)
	Flavivirus	Yellow fever virus	Mosquito (Aedes sp.)
	Flavivirus	West Nile Virus	Mosquito (Culex sp.)
	Flavivirus	St. Louis Encephalitis virus	Mosquito (Culex sp.)
Flaviviridae	Flavivirus	Japanese encephalitis virus	Mosquito (Culex sp.)
	Flavivirus	Murray Valley encephalitis virus	Mosquito (Culex sp.)
	Flavivirus	Usutu	Mosquito (various)
	Flavivirus	Omsk Hemorrhagic fever virus	Tick (dermacentor)
	Flavivirus	Kyasanur Forest Disease virus	Tick (Haemaphysalis sp.)
	Flavivirus	Tick-borne encephalitis virus	Tick (Ixodes and Haemaphysalis sp.)
	Flavivirus	Powassan virus	Tick (Ixodes sp.)
Orthomyxoviridae	Thogotovirus	Bourbon virus	Tick (A. americanum)
Reoviridae	Coltivirus	Colorado tick fever	Tick (dermacentor)
Rhabdoviridae	Vesiculovirus	Vesicular Stomatitis (New Jersey) virus	Sandflies (Lutz. Sp.)   Mosquitos (various)
	Vesiculovirus	Chandipura	Sandfly (Phlebotomus Sp.)
Togaviridae	Alphavirus	Barmah Forest Virus	Mosquito (Aedes and Culex sp.)
	Alphavirus	Chikungunya virus	Mosquito (Aedes sp.)
	Alphavirus	Venezuelan equine encephalitis virus	Mosquito (Culex sp.)
	Alphavirus	Sindbis virus	Mosquito (Culex sp.)
	Alphavirus	Equine encephalitis virus	Mosquito (Culex sp.)
	Alphavirus	Mayaro virus	Mosquito (Haemagogus sp.)



# Public health management of arboviruses


- Understand host/virus/vector transmission drivers
- Improve diagnostics and surveillance
- Increase entomology capacity and surveillance
- Strengthen communication and risk detection between countries
- Use genomics to monitor arboviral genotypes
- Build and strengthen partnerships and collaboration




# One Health approach

- Environmental surveillance of both vectors and animals is an important consideration
- Particularly monitoring amplifying hosts/sylvatic cycles


DENV transmission cycle



JEV transmission cycle



ZIKA transmission cycle





# Public health action

It is widely recognized that no strategy alone can fully address the problem. However, some intervention tools have helped reduce the disease burden.


- Vector control, including insecticide treatment and environmental management
  - residual spraying to reduce mosquito populations
- Personal protection
- Clinical diagnosis and management, laboratory-based surveillance
  - To guide access to clinical services
- Vaccination
  - Vaccines are available to protect against Japanese encephalitis and yellow fever, and the first dengue vaccine licensed in 2015




# Use cases for arboviral genomic surveillance

- Essential for early warning of virus outbreaks
- Understanding epidemic potential of endemic and newly introduced virus strain
- Early introduction of new strains into naive populations
- Detection of emergence of more virulent lineages and virus lineages resistant to interventions such as vaccines, antiviral drugs, and various vector control interventions (eg, *Wolbachia*-spp-infected mosquito strategies)
- Evaluation of intervention effectiveness
- Characterisation of the transmission network between vertebrates, including humans, and vector species
- Detection of genomic variants that could affect molecular assays.

Pathogen Genomics Utility



# Challenges to arboviral genomic surveillance



- Viremia is short lived
- Viremia peaks prior to acute symptoms
- Low level of symptomatic disease
- High diagnostic reliance on serological testing (which can be highly cross-reactive)

# Integrated Surveillance of Arboviruses

Integrated Dengue  
Surveillance





# Genomics use case


## Zika genomics in Singapore





# Zika case study - Singapore

- In 2016 (from Aug 27 to Nov 30), an outbreak of Zika virus infection (with 455 cases) were confirmed in Singapore.
- Zika virus was detected in the blood samples of 97 (60%) patients and the urine samples of 157 (96%) patients




*Singapore Zika Study Group, 2017, Lancet ID*



# Zika case study - Singapore

- In 2016 (from Aug 27 to Nov 30), 455 cases of Zika virus infection were confirmed in Singapore.
- Zika virus was detected in blood samples of 97 (60%) patients and urine samples of 157 (96%) patients.
- 15 clusters of cases, with the largest cluster traced back to workers from a construction site.

Zika cases



*Singapore Zika Study Group, 2017, Lancet ID*



# Zika case study - Singapore



*Aedes aegypti* breeding sites

- In 2016 (from Aug 27 to Nov 30), 455 cases of Zika virus infection were confirmed in Singapore.
- Zika virus was detected in blood samples of 97 (60%) patients and urine samples of 157 (96%) patients.
- 15 clusters of cases, with the largest cluster traced back to workers from a construction site.
- 12 of the cluster neighborhoods had a high percentage of *Aedes Aegypti* breeding sites. (2% PCR positive rate)



*Singapore Zika Study Group, 2017, Lancet ID*

Captured mosquitoes were pooled for Zika virus screening; nine abdomen pools (2%) were positive for Zika virus.



# Zika case study - Singapore

- Zika virus was sequenced from positive urine or serum clinical samples and mosquito samples.
- Sequenced using a full genome sequencing via a hybridization enrichment method. Using Illumina.
- 117 complete /nearly complete genomes (from 103 individual human samples and 14 mosquitoes).

## Conclusions

- The lineage showed little diversity and was distinct from other Asian lineages.
- The estimated most recent common ancestor of the outbreak lineage was from May, 2016.
- Possibility of 3 separate introductions.
- Increased vector control measures.




Figure 3: Temporal scale of the expansion of the Zika virus Asian genotype




# Genomics use case JEV Outbreak in Australia






# Japanese encephalitis virus

- Most JEV infections are mild or asymptomatic
- Approximately 1 in 250 results in severe disease
- 68,000 cases of clinical disease annually and ~15,000 deaths
- Naturally infects wading birds
- Pigs amplifying hosts



# Phylogeography of JEV



- Five distinct genotypes of JEV are recognised (I–V)
- Traditionally differentiated with E gene sequencing
- Genotypes I, II and III are the most prevalent and account for 98% (1935 to 2009)
- Vaccine is GIII

# JEV in southeastern Australia

In March 2022, the first JEV outbreak in mainland Australia was identified


45 people have been infected with JEV in Australia, seven deaths

JEV detected in 80 piggeries from four states

JEV vaccination targeted to protect those at greatest risk of infection



# NSW Case Detections



**n = 12**

**Median age: 49.7 years**

IQR 30.4 to 65.9 years

Range 10.1 to 73.7 years

**Male:Female ratio 2.0**

1 paediatric case – diagnosed by serology

First 3 months of outbreak:

1.5 JE cases per 1,000,000 population (NSW)

Prevalence of non-encephalitic disease unknown

Slide courtesy: Annaelise Howard-Jones



# Clinical utility of JEV genomics



**Table 3.** Diagnostic results for the twelve confirmed cases of Japanese encephalitis from New South Wales tested in our laboratory over the period 4 March 2022 to 31 May 2022.

Case #	CSF JEV IgM IF *	Serum JEV IgM IF *	Serum JEV IgG (Interval)	JEV RT-PCR	mNGS	Confirmed/Probable JE
1	detected	detected	>8× titre rise (7 days)	detected (brain tissue and CSF)	JEV sequence detected (brain tissue)	confirmed
2	not detected	not detected	not detected	detected (CSF)	-	confirmed
3	not detected	detected	4× titre rise (29 days)	not detected (CSF)	-	confirmed
4	-	detected	>4× titre rise (7 days)	-	-	confirmed
5	-	detected	falling IgG titres	-	-	confirmed
6	-	detected	4× titre rise (36 days)	-	-	confirmed
7	-	detected	>16× titre rise (9 days)	-	-	confirmed
8	-	detected	>4× titre rise (25 days)	-	-	confirmed
9	-	detected	>4× titre rise (19 days)	-	-	confirmed
10	-	detected	detected; no convalescent serum available	-	-	confirmed
11	-	detected	detected; no convalescent serum available	-	-	confirmed
12	-	detected	>8× titre rise (41 days)	-	-	confirmed

CSF, cerebrospinal fluid; IF, immunofluorescence; JE, Japanese encephalitis; JEV, Japanese encephalitis virus; mNGS, metagenomic next generation sequencing; RT-PCR, real-time polymerase chain reaction; \* for all samples in which JEV IgM was detected by IF, MVEV and WNVKUNV IgM (and dengue, yellow fever and/or Zika IgM if appropriate travel history) was performed by IF and found to be negative.






# JEV in southeastern Australia



2021 sentinel detection JEV Genotype IV




# Genomics for JEV



JEV amplicon tiling  
Cost: ~\$200  
Time: 24 – 48hours

Metagenomics  
Cost: ~\$1000  
Time: 12 – 24hours




# One health genomic surveillance



The screenshot shows the NSW Health website with the following elements:

- Header:** NSW Health logo and a search bar.
- Navigation:** COVID-19, Public, Healthy living, Professionals, Research, Careers, Publications, Media, About, Ministers.
- Breadcrumbs:** Home > Infectious diseases > Mosquito borne diseases > Mosquito-borne disease surveillance.
- Left Sidebar:** Mosquito borne diseases, Bite prevention, Mosquito reduction, Vaccination, Resources, Surveillance.
- Main Content:**
  - Mosquito-borne disease surveillance**
  - On this page**
    - [NSW Arbovirus Surveillance and Mosquito Monitoring Program](#)
    - [Weekly report](#)
    - [Mosquito monitoring](#)
    - [Sentinel chicken surveillance](#)
    - [Mosquito trapping videos](#)
    - [Serosurvey](#)
  - Surveillance and monitoring**
    - [Season 2022-23 weekly reports](#)
    - [Season 2021-22 weekly reports](#)
    - [Season 2020-21 weekly reports](#)



# Vector surveillance



- *Culex annulirostris* primary vector for the 2022 JEV outbreak
- Widespread across mainland Australia
- Freshwater habitats including natural and constructed wetlands
- Opportunist feeding on a wide range of animals: birds, pigs, humans
- Can disperse up to 12km from larval habitats
- Demonstrated capacity to transmit various arboviruses including JEV (EIP 7-10 days post infection)








Slide courtesy: Annaelise Howard-Jones

# Strengths of genomics for arboviral surveillance

- First detection of genotype IV in a temperate climate
- Genomic surveillance revealed circulation of genotype IV in Tiwi Islands in 2021
- One health surveillance key to clearly identifying the causal genotype
- Diagnostic challenges for rare and unusual arboviruses overcome using metagenomics

## Whole genome Phylogenetics







## Activity 1

“Using genomics for Arboviral outbreaks”



# Group case studies

- Each scenario can be conducted at your current table as a team
- Each team address key questions that assist when implementing genomic surveillance during an arboviral outbreak
- Please outline on the slide templates/easel with butchers' paper below key drivers and barriers to conducting genomic surveillance in your scenario
- Results will be presented to the group during an open discussion



# Capacity for genomics surveillance

## Low capacity

- Multiple arboviruses usually **endemic**
- High startup cost could mean minimal interest in genomics for arboviral control.

## Moderate capacity

- Frequent seasonal outbreaks of arbovirus
- Genomics could be used to strengthen arbovirus control activities
- More stringent inclusion criteria for sequencing

## High capacity


- Frequent seasonal outbreaks of arbovirus
- Genomics to aid preparedness, vector control and targeted vaccination
- Replace partial genome sequencing



# Case assignments

## Moderate capacity

- Frequent seasonal outbreaks of arbovirus
- Genomics could be used to strengthen arbovirus control activities
- More stringent inclusion criteria for sequencing



## High capacity

- Low arboviral incidence
- Genomics to aid preparedness, vector control and targeted vaccination
- Replace partial genome sequencing



# Assumptions for exercise

- In all scenarios, the assumption will be that the diagnostic/public health laboratory is fully stocked and can conduct molecular testing for a range of arboviruses
- Sampling, genomics capacity and genomic activities will be unique in each case.



# Questions for considerations

- What are the likely uses of genomics in your scenario ?
- Outline potential sectors and surveillance partners to address the main aim of the scenario?
- What would be the most feasible and cost-effective sampling strategy?
- Does the scenario setting have sufficient capacity to address the main aim of genomics surveillance? If insufficient, what actions can be taken to strengthen in an outbreak scenario?
- Who are the target reporting stakeholders and how often should reports be generated?
- What are the key barriers to implementing genomic surveillance within existing surveillance systems for your pathogen?





# Setting the scene: Group 1

High capacity

Pathogen	Dengue
Aim	A new vaccine is about to be rolled out in a country with multiple circulating serotypes of Dengue. MOH is keen to use genomics along with other complimentary methods to assess the impact of vaccination on circulating dengue viruses in the country.
Case numbers	Hyper-endemic with high seasonal case numbers
Current genomics activities	<ul style="list-style-type: none"><li>• Convenience sampling of Dengue cases for E gene Sanger sequencing</li><li>• Routine SARS-CoV-2 genomic surveillance</li><li>• Other traditional surveillance methods such as PCR, serology assays for Dengue are available.</li></ul>
Sequencing platforms (status)	<ul style="list-style-type: none"><li>• Illumina Nextseq 2000</li><li>• Oxford Nanopore GridION (have access if required)</li></ul>



# Setting the scene: Group 2

Moderate capacity

Pathogen	Zika virus
Aim	<p>There has been a recent increase of microencephaly in newborns. In a private hospital, a case has come up PCR positive for Zika virus.</p> <p>Zika is not new to this Asian country, although not previously linked with microencephaly. MOH is keen to sequence the circulating strains to inform treatment and control response.</p>
Case numbers	5 cases of microencephaly within two months
Current genomics activities	<ul style="list-style-type: none"><li>• Dengue sequencing capacity, but not routinely conducted</li><li>• SARS-CoV-2 genomic surveillance</li><li>• Other traditional surveillance methods such as PCR, serology assays for Zika are available.</li></ul>
Sequencing platforms (status)	<ul style="list-style-type: none"><li>• Illumina Nextseq 500 (workhorse)</li><li>• Oxford Nanopore GridION (have access if required)</li></ul>



# Setting the scene: Scenario 3

Moderate capacity

Pathogen	Japanese encephalitis virus (JEV)
Aim	In a <u>non-endemic</u> country, there has been a case of encephalitis that is PCR confirmed to be JEV. The case has no history of travel. The MOH is keen to investigate with genomics the possible exposure event.
Case numbers	>50 RT-PCR confirmed cases
Current genomics activities	Genomic surveillance of Dengue virus only Samples of convenience used for dengue surveillance
Sequencing platforms	<ul style="list-style-type: none"><li>• Illumina iSeq</li><li>• Oxford Nanopore GridION</li></ul>



# Setting the scene: Scenario 4

High capacity

Pathogen	Arbovirus X
Aim	An outbreak of severe febrile illness with neurological symptoms is occurring. Coincidental deaths of birds at the zoo have also been reported. Serum antibodies give weak signal to dengue, hence it is suspected the outbreak maybe caused by a flavivirus.
Case numbers	>100 cases
Current genomics activities	<ul style="list-style-type: none"><li>• Whole genome sequence of Dengue cases only</li><li>• Other traditional surveillance methods such as PCR, serology assays are only available for dengue.</li></ul>
Sequencing platforms (status)	<ul style="list-style-type: none"><li>• Illumina Nextseq 500 (workhorse)</li></ul>



# Template for team answers

- What are the likely uses of genomics in your scenario ?
- Outline potential sectors and surveillance partners to address the main aim of the scenario?



# Template for team answers

- What would be the most feasible and cost-effective sampling strategy?
- Does the scenario setting has sufficient capacity to address the main aim of genomics surveillance? If insufficient what actions can be taken to strengthen in an outbreak scenario?





# Template for team answers

- Who are the target reporting stakeholders and how often should reports be generated?
- What are the key barriers to implementing genomic surveillance within existing surveillance systems for your pathogen?





## Activity 2

# Pathogen Prioritization for Dengue



# Pathogen prioritisation activity



# Pathogen Prioritization for Dengue





# Thank you!

## WORKSHOP PARTNERS



# Resources

- Sequencing protocols:
  - WNV (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10305458/>)
  - Dengue (<https://www.protocols.io/view/denguese-q-a-pan-serotype-whole-genome-amplicon-seq-kqdg39xxeg25/v3>)
  - WNV, Dengue, Zika, YF, CHIK, Lassa  
([https://docs.google.com/spreadsheets/d/1zMfUv1IV5-Sy-AeOPhKHdoZMUxhD1R\\_RsB5gPswqx40/edit?pli=1&gid=0#gid=0](https://docs.google.com/spreadsheets/d/1zMfUv1IV5-Sy-AeOPhKHdoZMUxhD1R_RsB5gPswqx40/edit?pli=1&gid=0#gid=0))
  - Make your own primer scheme (<https://www.protocols.io/view/primalseq-generation-of-tiled-virus-amplicons-for-n2bvjyqw5vk5/v>)

